Prognostic Accuracy of Three COPD Classification Systems in Relation to Long-Term Mortality of COPD Patients: A Prospective Multicenter Study
- 42 Downloads
Recent research showed group B patients express higher mortality compared to group C patients when GOLD A-D grouping is used. We aimed to compare the prognostic accuracy of three GOLD classification systems, I–IV (“pre-2011”), A-D (“2011–2016”) and A-D (“2017–present”) in relation to mortality, exacerbation risk, quality of life (QoL) assessment and specific treatments use in a real-life COPD cohort. We used the data of 720 patients from the Czech Multicenter Research Database of COPD. Four-year mortality and time-to-exacerbation using the GOLD “pre-2011”, “2011–2016” and “2017–present” classification schemes were assessed. Moreover, distribution of specific treatments use and QoL measures were analyzed. The GOLD I-IV classification system showed gradual increase in 4-year mortality across the stages (GOLD II 18.8%, III 28.5%, IV 38.7%) (p = 0.001). Using the A-D “2011–2016” classification scheme, group C patients had lower mortality (16.7%) than group B (18.7%) (p = 0.009). The A-D “2017–present” classification showed higher mortality in group B (25.5%) compared to group C (20%) (p = 0.05). For additional outcomes, the GOLD I–IV scheme showed highest match between the calculated 4-year exacerbation risk and QoL measures and GOLD stage/grouping. In terms of specific treatment distributions, various patterns for each GOLD classification system were observed with best match of GOLD “2017–present” system to the layout of GOLD groups and categories. We conclude the GOLD I–IV classification system had the highest accuracy related to mortality, QoL measures and exacerbation risk prediction, while the A-D “2017–present” scheme was most accurate within severity of symptoms prediction reflected also by more frequent specific treatments use.
KeywordsCOPD GOLD classification Prognosis Mortality
We thank the physicians of participating centers of the CMRD project.
This research was funded by Ministry of Health of the Czech Republic (15/14/NAP; 5/15/NAP; UHHK 00179906 and FNBr 65269705) and by a consortium of pharmaceutical companies (Angelini CZ, AstraZeneca CZ, Boehringer Ingelheim CZ, Cipla CZ, CSL Behring CZ, GSK CZ, Novartis CZ and Sandoz CZ).
Compliance with Ethical Standards
Conflict of interest
The authors declare no conflicts of interest in relation to the presented work.
- 1.GOLD 2017 Global Strategy for the Diagnosis, Management and prevention of COPD. global initiative for chronic obstructive lung disease. http://goldcopd.org/gold-2017-global-strategy-diagnosis-management-prevention-copd/. Accessed 12 July 2018
- 2.Rabe KF, Hurd S, Anzueto A, Barnes PJ, Buist SA, Calverley P et al (2007) Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 176:532–555CrossRefGoogle Scholar
- 4.Global Strategy for Diagnosis, Management, and Prevention of COPD – (2016) Global Initiative for Chronic Obstructive Lung Disease. http://goldcopd.org/global-strategy-diagnosis-management-prevention-copd-2016/. Accessed 12 July 2018
- 6.Tudoric N, Koblizek V, Miravitlles M, Valipour A, Milenkovic B, Barczyk A et al (2017) GOLD 2017 on the way to a phenotypic approach? Analysis from the phenotypes of COPD in central and Eastern Europe (POPE) cohort. Eur Respir J 49:1602518. https://doi.org/10.1183/13993003.02518-2016 CrossRefGoogle Scholar
- 13.Miravitlles M, Soler-Cataluña JJ, Calle M, Molina J, Almagro P, Quintano JA et al (2017) Spanish guidelines for management of chronic obstructive pulmonary disease (GesEPOC) 2017. Pharmacological treatment of stable phase. Arch Bronconeumol 53:324–335. https://doi.org/10.1016/j.arbres.2017.03.018 Google Scholar